Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ.
about
Nanobodies raised against monomeric ɑ-synuclein inhibit fibril formation and destabilize toxic oligomeric species.Emerging Disease-Modifying Strategies Targeting α-Synuclein for the Treatment of Parkinson Disease.Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson's disease model
P2860
Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ.
@ast
Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ.
@en
type
label
Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ.
@ast
Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ.
@en
prefLabel
Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ.
@ast
Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ.
@en
P2093
P2860
P1433
P1476
Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ.
@en
P2093
Anne Messer
David C Butler
Erwin De Genst
Shubhada N Joshi
P2860
P304
P356
10.1371/JOURNAL.PONE.0165964
P407
P577
2016-11-08T00:00:00Z